Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions

The advent of immunotherapy has revolutionized cancer treatment. Unfortunately, this has not been the case for metastatic castration-resistant prostate cancer (mCRPC), likely due to the heterogeneous and immune-suppressive microenvironment present in prostate cancer. The identification of molecular...

Full description

Bibliographic Details
Authors: Lopez-Campos, F, Gajate, P, Romero-Laorden, N, Zafra-Martin, J, Juan, M, Polo, SH, Moreno, AC, Counago, F
Format: article
Status:Published version
Publication Date:2022
Country:España
Institution:Fundació Sant Joan de Déu
Repository:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
OAI Identifier:oai:fsjd.fundanetsuite.com:p22634
Online Access:https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=22634
Access Level:Open access
Keyword:immunotherapy
metastatic castration-resistant prostate cancer
advanced prostate cancer
cancer vaccines
immune checkpoints inhibitors
id ES_3f7c67e4b7a2e8dce6962f7b3095aa8d
oai_identifier_str oai:fsjd.fundanetsuite.com:p22634
network_acronym_str ES
network_name_str España
repository_id_str
spelling Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future DirectionsLopez-Campos, FGajate, PRomero-Laorden, NZafra-Martin, JJuan, MPolo, SHMoreno, ACCounago, Fimmunotherapymetastatic castration-resistant prostate canceradvanced prostate cancercancer vaccinesimmune checkpoints inhibitorsThe advent of immunotherapy has revolutionized cancer treatment. Unfortunately, this has not been the case for metastatic castration-resistant prostate cancer (mCRPC), likely due to the heterogeneous and immune-suppressive microenvironment present in prostate cancer. The identification of molecular biomarkers that could predict response to immunotherapy represents one of the current challenges in this clinical scenario. The management of advanced castrationresistant prostate cancer is rapidly evolving and immunotherapy treatments, mostly consisting of immune checkpoint inhibitors combinations, BiTE (R) (bispecific T-cell engager) immune therapies, and chimeric antigen receptors (CAR) are in development with promising results. This review analyses the current evidence of immunotherapy treatments for mCRPC, evaluating past failures and promising approaches and discussing the directions for future research.MDPI2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=22634BiomedicinesISSN: 22279059reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déuinstname:Fundació Sant Joan de DéuInglésinfo:eu-repo/semantics/openAccessoai:fsjd.fundanetsuite.com:p226342026-05-27T12:37:41Z
dc.title.none.fl_str_mv Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions
title Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions
spellingShingle Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions
Lopez-Campos, F
immunotherapy
metastatic castration-resistant prostate cancer
advanced prostate cancer
cancer vaccines
immune checkpoints inhibitors
title_short Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions
title_full Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions
title_fullStr Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions
title_full_unstemmed Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions
title_sort Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions
dc.creator.none.fl_str_mv Lopez-Campos, F
Gajate, P
Romero-Laorden, N
Zafra-Martin, J
Juan, M
Polo, SH
Moreno, AC
Counago, F
author Lopez-Campos, F
author_facet Lopez-Campos, F
Gajate, P
Romero-Laorden, N
Zafra-Martin, J
Juan, M
Polo, SH
Moreno, AC
Counago, F
author_role author
author2 Gajate, P
Romero-Laorden, N
Zafra-Martin, J
Juan, M
Polo, SH
Moreno, AC
Counago, F
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv immunotherapy
metastatic castration-resistant prostate cancer
advanced prostate cancer
cancer vaccines
immune checkpoints inhibitors
topic immunotherapy
metastatic castration-resistant prostate cancer
advanced prostate cancer
cancer vaccines
immune checkpoints inhibitors
description The advent of immunotherapy has revolutionized cancer treatment. Unfortunately, this has not been the case for metastatic castration-resistant prostate cancer (mCRPC), likely due to the heterogeneous and immune-suppressive microenvironment present in prostate cancer. The identification of molecular biomarkers that could predict response to immunotherapy represents one of the current challenges in this clinical scenario. The management of advanced castrationresistant prostate cancer is rapidly evolving and immunotherapy treatments, mostly consisting of immune checkpoint inhibitors combinations, BiTE (R) (bispecific T-cell engager) immune therapies, and chimeric antigen receptors (CAR) are in development with promising results. This review analyses the current evidence of immunotherapy treatments for mCRPC, evaluating past failures and promising approaches and discussing the directions for future research.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=22634
url https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=22634
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Biomedicines
ISSN: 22279059
reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname:Fundació Sant Joan de Déu
instname_str Fundació Sant Joan de Déu
reponame_str r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
collection r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869406636221661184
score 15,81155

Similar Items